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Introduction: Selecting the appropriate treatment strategy for pa-
tients with locally advanced non-small cell carcinoma (NSCLC) is
of utmost importance to determine patient outcome. Previous studies
have shown that nodal down-staging after induction therapy and
definitive local irradiation in these patients better predict survival
when combined with surgery. However, nodal restaging can be
technically difficult. We investigated the role of transbronchial
needle aspiration (TBNA) in mediastinal restaging of patients who
had completed induction cytotoxic therapy.
Methods: A total of 14 patients with proven stage IIIa-N2 NSCLC
who received chemotherapy or chemo-radiotherapy as induction
regimen between 2005 and 2006 were studied. Outpatient flexible
bronchoscopy with TBNA was performed in all patients under local
anesthesia, and 17 TBNA procedures were performed. TBNA re-
sults were matched against the histopathology of surgical specimens.
Results: Seventeen lymph nodes in 14 patients who had undergone
induction therapy were sampled. Positron emission tomography
(PET) scan results of 11 patients were also available for comparison.
All positive TBNA procedures had positive PET scans. However,
for five patients with lymph nodes measuring 9 to 17 mm, the PET
scans were falsely positive, as mediastinoscopy and subsequent
surgically resected lymph nodes revealed no tumor. TBNA achieved
a correct diagnosis in 71% of patients who underwent mediastinal
restaging and obviated further need for invasive procedures in 35%.
Conclusion: For patients presenting with locally advanced NSCLC
who are surgical candidates after induction chemo- and/or radiother-
apy, TBNA should be considered as the initial procedure of choice
for restaging of the mediastinum.
Key Words: Transbronchial needle aspiration, Induction therapy,
Mediastinum, Nodal restaging.
(J Thorac Oncol. 2007;2: 912–915)
In recent years, progress has been made in the managementof lung cancer because of improvement in staging tech-
niques. Selecting the appropriate treatment strategy for a
patient is of utmost importance for patient outcome. It has
been shown that mediastinal nodal down-staging in patients
with locally advanced non-small cell lung cancer (NSCLC)
predicts survival after induction chemo-radiotherapy.1–4 Pa-
tients who have down-staged N2 disease may benefit from
surgical resection, although up to 33% of resected patients
might experience subsequent disease relapse.1–5 The use of
concurrent chemo-radiotherapy has been shown to be a very
effective approach for nodal down-staging and lung cancer
treatment.5 The radiation dose to the mediastinum must be
greater than 66 Gy to be curative, but the main disadvantage
of high-dose radiotherapy is the development of local fibrosis
and adhesions, which makes it technically difficult to perform
subsequent surgery.6,7 Therefore, nodal down-staging has
been performed at a lower radiation dose (45 Gy), but the
window among neo-adjuvant therapy, mediastinal restaging,
and definitive treatment should be as short as possible to
prevent repopulation of cancer cells.8,9
Currently, a number of different techniques are avail-
able for investigating the initial pathological status of the
mediastinal lymph nodes or for restaging. Computed tomog-
raphy (CT) and positron emission tomography (PET) are not
sufficient, as histological confirmation is required.5,10 An-
nema et al. reported the use of endoscopic ultrasound (EUS)
for restaging in 19 patients, but not all nodal stations were
accessible, and no data on EUS after chemo-radiotherapy
were available.11–13 Bronchoscopy with transbronchial needle
aspiration (TBNA) is an established technique to sample
nodes in the mediastinum, but the reported diagnostic yield is
highly variable, with a meta-analysis reporting the pooled
sensitivity and specificity to be only 39% (95% CI, 17–61)
and 99% (95% CI, 96–100), respectively.14 The yield of
conventional TBNA has been higher for bulky lymph nodes.14
In recent years, many investigators have evaluated the medias-
tinum with endobronchial ultrasound (EBUS) and have reported
excellent results, but these procedures are performed in patients
who had no prior treatment.14 The notable advantage of TBNA
with or without EBUS is that it is a rapid, feasible technique
by which an immediate pathological diagnosis can be made
on-site.15 We report the yield of TBNA procedure in patients
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who received chemotherapy and radiation therapy for locally
advanced pathological Stage IIIA NSCLC.
PATIENTS AND METHODS
Patients with pathologically proven stage IIIA-N2
NSCLC who had received induction chemotherapy and/or
radiotherapy as part of their standard of care from 2005 to
2006 were included. Initial staging was performed with PET
and CT scanning within a month for treatment, according to
the Dutch guidelines for NSCLC. All patients had patholog-
ically proven stage IIIa-N2 NSCLC by TBNA. Treatment
consisted of either chemo-radiotherapy or chemotherapy
alone. Combined chemo-radiotherapy was routinely used at
our hospital, and patients referred from other hospitals had
received induction chemotherapy. In the combination arm,
the chemotherapy consisted of cisplatin 20 mg/m2 and do-
cetaxel 20 mg/m2 weekly for 6 consecutive weeks and radio-
therapy starting from day 8 up to 60 Gy. The induction
treatment with chemotherapy alone consisted cisplatin 80
mg/m2 (day 1) and gemcitabine 1250 mg/m2 (day 8) repeated
every 3 weeks for three cycles.
Restaging procedures were performed 2 weeks after the
third cycle of cisplatin and gemcitabine, at radiation dose of
45 Gy. These consisted of PET scanning and flexible bron-
choscopy with TBNA performed under local anesthesia.
When the TBNA results of the mediastinal nodes sampled
were reported as negative, a cervical mediastinoscopy was
performed within a week of discontinuation of radiotherapy.
If nodal metastases persisted, radiotherapy was restarted
within 5 working days to a dose greater than 60 Gy. If
mediastinoscopy confirmed the absence of nodal metastasis, a
thoracotomy with the aim of a radical resection including
mediastinal lymph node dissection was performed within 2
weeks. All patients gave informed consent for staging proce-
dures, and the study protocol was approved by local ethics
committee.
Before TBNA, all patients had chest CT with contrast
enhancement at 5-mm cuts from the thoracic inlet to carina
and from inferior pulmonary veins to the diaphragm. TBNA
was performed using a 19-gauge cytology needle (Boston
Scientific Benelux, Maastricht, the Netherlands). Four TBNA
passes were performed at each site, and selection of the
lymph node for TBNA was left to the discretion of an
experienced bronchoscopist after review of imaging studies
and previous TBNA results. No rapid on-site cytological
evaluation was used, and all specimens were submitted as dry
smears.
Clinical characteristics, lymph node stations according
to American Thoracic Society (ATS) classification, size of
lymph node measured by its short-axis diameter on CT, final
surgical pathological diagnosis after mediastinoscopy and/or
thoracotomy, and PET scan results were recorded.
Statistical Analysis
Data were entered onto a spreadsheet. Values were
expressed as frequency and percentages.
RESULTS
Seventeen lymph nodes from 14 patients who had
undergone induction therapy for stage IIIa-N2 NSCLC were
sampled. Table 1 shows the characteristics of the patients. All
but two patients received chemoradiation as the induction
regimen. No complications resulting from the bronchoscopy
and TBNA procedure were recorded. Mediastinoscopy was
TABLE 1. Patient Characteristics and Transbronchial Needle Aspiration, Positron Emission Tomography, and Surgical
Histopathology Results
Patient
Age
(yr) Sex
Initial N2 Metastasis
(Naruke station)
TBNA Result
(adeno/SCC)
Definitive Diagnosis
(adeno/SCC) FDG-PET Result
Nodal Diameter
(short axis, mm)
1 55 F 7 Not representative Negative Positive 17
2 58 M 4R Atypia NA Positive 9
3 73 M 7 Negative Negative NA 14
4 57 F 4R Negative NA NA 18
5 58 F 3 Negative Negative NA 5
6 57 M 4R Negative NA NA 32
7 68 M 4R Negative Negative Positive 11
7 68 M 7 NSCLC NSCLC Positive 14
8 56 F 4R Negative Negative Negative 12
8 56 F 7 Negative Negative Positive 20
9 61 F 7 Negative Negative Negative 16
10 51 M 4R NSCLC — Positive 18
10 51 M 7 NSCLC — Positive 12
11 66 F 4L NSCLC — Positive 40
12 66 F 4R NSCLC — NA 8
13 43 M 7 NSCLC — NA 25
14 49 M 4R NSCLC — Positive 20
TBNA, transbronchial needle aspiration; adeno, adenocarcinoma; SCC, small cell carcinoma; FDG-PET, positron emission tomography; NSCLC, non-small cell lung cancer; NA,
not applicable.
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not performed in three patients: patient 6 experienced arterial
thrombosis after chemotherapy, and it was therefore decided
to continue treatment with radiotherapy. Although the cyto-
logical result of patient 2 showed atypia, radial endobronchial
ultrasound demonstrated tracheal invasion, and the patient was
continued on radiotherapy. In patient 1, the TBNA aspirate was
considered non-representative and thus regarded as a procedure
failure. Because of the clinician’s doubt regarding the TBNA
result, although patient 7 had a positive result at lnn 7, the patient
underwent mediastinoscopy as lnn 4R (initially proven to be
positive) showed a negative result.
In six lymph nodes samples, no malignant cells were
found on both TBNA aspirates and biopsies by mediastinos-
copy, and these patients subsequently underwent thoracot-
omy, which confirmed the negative findings. For the remain-
ing seven lymph node samples with persistent tumor on
TBNA, the corresponding patients were treated with a radical
dose of radiotherapy. Therefore, true negative results and
positive results of lymph nodes samples were found in 14 of
17 lymph nodes (81%). TBNA correctly diagnosed the state
of mediastinal nodes for 10 patients (71%), and 5 patients
(35.7%) did not require further exploration.
PET scan results were available for 11 patients. All
positive TBNA procedures in these patients had positive PET
scans. However, five patients with lymph nodes measuring 9
to 17 mm had false-positive PET scans, as mediastinoscopy-
guided lymph node biopsies and later examination of surgi-
cally resected lymph nodes revealed no tumor.
DISCUSSION
Simple and quick techniques that facilitate tissue bi-
opsy from the mediastinum are necessary for optimal treat-
ment planning in patients with stage IIIa-N2 NSCLC. A
number of techniques, including FDG- PET, integrated PET-
CT, and endoscopic techniques (i.e., EBUS), have recently
been developed to investigate the mediastinum.16–20 Selec-
tion of patients after induction therapy for surgical therapy is
still a moving field. Because it is generally accepted that
mediastinal down-staging is important, the question is how to
assess this in the most reliable way. Response evaluation after
chemo-radiotherapy by serial CT scans can be difficult, as
significant gross residual tumor may be present at thoracot-
omy in up to 40% of patients with radiological stable disease
and in 27% of the patients with a partial response.5 Recent
studies have shown that integrated PET-CT improves sensi-
tivity without compromising specificity compared with stand-
alone PET.16 However, reliance on imaging alone is unac-
ceptable, and a tissue diagnosis is still required to guide
management.10 A single-center study reported that after a
thorough staging mediastinoscopy, remediastinoscopy after
induction therapy had a disappointingly low sensitivity be-
cause of adhesions and fibrosis.10
However, the impact of tumor necrosis on the diagnos-
tic yield with different staging techniques is not known.
In this study, TBNA (in experienced hands) was found
to be an easy and rapid technique with good results after
chemoradiation, and it resulted in a reduction in surgical
staging procedures. TBNA can access stations Naruke 4R, 7,
4L, 2L, and 2R. It is not possible to reach 5, 6, 8, and 9
endobronchially,21–23 but they can be reached by endo-esoph-
ageal ultrasound with reportedly good results after chemo-
therapy.11 Whether the yield in this study can be increased by
performing EBUS13,23,24 is doubtful given the results of the
surgical staging procedure in our patients. Larger series with
EBUS real-time punctures have already proven to have a
superior yield compared with TBNA,13 but this remains to be
proven for restaging. Because equipment for EBUS real-time
TBNA is costly and is therefore not available in every
hospital, the present results indicate a need to use TBNA
more widely. That this still is not the case may be the result
of a lack of experience, bronchoscopic damage, or failure to
reproduce results in the literature.25,26 The low yields men-
tioned for TBNA in the literature14 may also be improved
upon with training and experience.25 Furthermore, the train-
ing could help to make this technique more widespread. In
this study, four TBNA passes were used for restaging, as the
superior amount of passes in normal staging is four to five.27
Considering the results of this study, we also recommend four
passes, although this was not thoroughly investigated.
As mentioned by Rami-Porta recently,4 in clinical prac-
tice, the staging and restaging of tumors should be performed
using techniques that can provide high clinical certainty of
nodal down-staging, as these are the only parameters associ-
ated with prolonged survival. TBNA procedure is one such
procedure, as may be concluded from our experience. It is
easy to perform and provides rapid results so that it does not
cause delay in the institution of further treatment. The study
has three limitations. First, the sample size is small. Second,
the lymph nodes sampled were also initially pathological
proven stage IIIa-N2 by TBNA. Third, although patients with
positive TBNA for residual tumor were not subjected to
mediastinoscopy (and the false-positive rate therefore could
not be accurately determined), we believe our findings are of
clinical relevance for pulmonologists managing patients with
stage IIIA NSCLC. This is the first study to demonstrate a
role for TBNA in the restaging of the mediastinum after
induction cytotoxic therapy.
CONCLUSION
Our experience suggests that TBNA should be the
initial procedure of choice in the restaging of the mediasti-
num for patients with stage IIIA NSCLC who may be
considered surgical candidates after induction chemo- and/or
radiotherapy.
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